Sanofi gets first ever approval within Niemann-Pick as Japan green-lights drug

As the first country in the world, Japan has approved a treatment, Sanofi-developed Xenpozyme, for Niemann-Pick disease type A, also known as acid sphingomyelinase deficiency (ASMD).
Photo: Benoit Tessier/Reuters/Ritzau Scanpix
Photo: Benoit Tessier/Reuters/Ritzau Scanpix
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Sanofi is the first and only company in the world to receive an approval for a drug targeting the disease acid sphingomyelinase deficiency (ASMD), Sanofi reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading